You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

31 Results
Guidelines and Advice
Status: Current
ID: PET 5
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 3
Jan 2009
Guidelines and Advice
Mar 2009
Guidelines and Advice
Status: Archived
ID: 3-16
Jul 2009
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-04-V2
Version: 2
Jan 2009
Statistical Reports
Guidelines and Advice
Jan 2009
Drug
Other Name(s): Procytox®
Oct 2020
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
Oct 2020
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Metastatic renal cell carcinoma, with specific criteria
Oct 2020
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Metastatic renal cell carcinoma of clear cell histology as second-line treatment, with specific criteria
Oct 2020

Pages